Clinical Trial Search

Primary: Number of Subjects Reporting at Least 1 Treat-Emergent Adverse Event (TEAE) During the Treatment Period (up to 8 Years) — 343 subjects

Primary: Number of Participants With 5-year Freedom From Prostate Specific Antigen (PSA) Recurrence. — 30 participants

Primary: Progression Free Survival (PFS) — 5.5 months — p=<0.0001

Primary: Inspiratory Capacity (IC) at Peak Time and at Isotime on Day 14 — 2.36; 2.05; 2.37; 2.10 Liters

Primary: Number of Children That Achieved Total (40 ml) or Partial (Less Than 40 ml But at Least 10 ml) Tolerance to Raw Egg — 9; 0 participants

Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of Each Treatment Period (Day 7) — 0.186; 0.190; 0.194; -0.021…

Primary: Objective Response Rate (ORR) — 11.1; 17.6; 10.6 percentage of participants

Primary: Objective Response (ORR) — 8.5; 5.9; 15.2 Percentage of patients

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Day 85. — -0.01; -0.19; -0.54; -0.56 percentage of Glycosylated Hemoglobin — p=0.001

Primary: Participant Response Rate — 7 Participants

Primary: Maximum Tolerated Dose (MTD) Oxaliplatin — 25 mg/m^2

Primary: The Number of Participants Who Achieved Clinical Pregnancy in a Transfer Cycle — 17; 7 participents — p=0.023

Primary: Live Birth Rate = (Number of Live Births / Total Number of Pregnancies) — 24; 20 Percentage of pregnancies

Primary: Number of Participants With the Indicated Overall Best Response (OBR) at Visit 26 (3 Months After the Last Infusion of Ofatumumab) — 6; 9; 10; 7 participants

Primary: Number of Participants With Complete Remission — 41 Participants